| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Omeros Corporation (NASDAQ: OMER)
OMER Technical Analysis
5
| As on 15th Oct 2025 OMER SHARE Price closed @ 10.42 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 6.08 & Strong Buy for SHORT-TERM with Stoploss of 3.78 we also expect STOCK to react on Following IMPORTANT LEVELS. |
OMERSHARE Price
| Open | 11.59 | Change | Price | % |
| High | 12.10 | 1 Day | 6.32 | 154.15 |
| Low | 9.19 | 1 Week | 5.81 | 126.03 |
| Close | 10.42 | 1 Month | 6.24 | 149.28 |
| Volume | 124785290 | 1 Year | 7.29 | 232.91 |
| 52 Week High 12.15 | 52 Week Low 2.97 | ||||
NASDAQ USA Most Active Stocks
| GNPX | 0.84 | 236.00% |
| AMRS | 0.14 | 100.00% |
| WBA | 11.98 | 0.50% |
| NVDA | 179.83 | -0.11% |
| PLUG | 3.85 | -4.94% |
| RXRX | 6.79 | 15.28% |
| BITF | 6.47 | 9.85% |
| NVTS | 15.16 | 20.60% |
| CAN | 1.96 | 8.89% |
| OMER | 10.42 | 154.15% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| OMER Daily Charts |
OMER Intraday Charts |
Whats New @ Bazaartrend |
OMER Free Analysis |
|
|
OMER Important Levels Intraday
| RESISTANCE | 16.03 |
| RESISTANCE | 14.23 |
| RESISTANCE | 13.12 |
| RESISTANCE | 12.01 |
| SUPPORT | 8.83 |
| SUPPORT | 7.72 |
| SUPPORT | 6.61 |
| SUPPORT | 4.81 |
OMER Forecast October 2025
| 4th UP Forecast | 12.62 |
| 3rd UP Forecast | 11.91 |
| 2nd UP Forecast | 11.48 |
| 1st UP Forecast | 11.04 |
| 1st DOWN Forecast | 9.8 |
| 2nd DOWN Forecast | 9.36 |
| 3rd DOWN Forecast | 8.93 |
| 4th DOWN Forecast | 8.22 |
OMER Weekly Forecast
| 4th UP Forecast | 11.58 |
| 3rd UP Forecast | 11.21 |
| 2nd UP Forecast | 10.98 |
| 1st UP Forecast | 10.75 |
| 1st DOWN Forecast | 10.09 |
| 2nd DOWN Forecast | 9.86 |
| 3rd DOWN Forecast | 9.63 |
| 4th DOWN Forecast | 9.26 |
OMER Forecast2025
| 4th UP Forecast | 30.94 |
| 3rd UP Forecast | 24.36 |
| 2nd UP Forecast | 20.29 |
| 1st UP Forecast | 16.22 |
| 1st DOWN Forecast | 4.62 |
| 2nd DOWN Forecast | 0.55 |
| 3rd DOWN Forecast | -3.52 |
| 4th DOWN Forecast | -10.1 |
Omeros Corporation ( NASDAQ USA Symbol : OMER )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
OMER Business Profile
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN), atypical hemolytic uremic syndrome (aHUS), and COVID-19; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consist of PPAR? (OMS405) to treat opioid and nicotine addiction; PDE7 (OMS527) for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington. Address: The Omeros Building, Seattle, WA, United States, 98119
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service